Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This is a first-in-human, pilot study of the feasibility and safety of dapagliflozin (in
addition to standard of care treatment) for the treatment of patients with metastatic
pancreatic ductal adenocarcinoma. The primary hypothesis is that dapagliflozin is
well-tolerated and safe to use in this patient population. The investigators also hypothesize
that dapagliflozin will be efficacious as an adjunct to front-line chemotherapy assessed by
decreased tumor markers mediated by its pleiotropic metabolic effects.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)